Introducing the innovative SARS-COV-2/Influenza A+B Antigen Combo Rapid Test Device by QL Biotech, specifically designed for the prompt and precise Detection of Canine C Reactive Protein. This breakthrough product is the result of QL Biotech's unrelenting commitment to quality assurance and medical innovation. The unique feature of our product is its dual specificity, targeting not only SARS-COV-2 but also Influenza A and B antigens, making it one of the most comprehensive rapid test devices on the market. The device is user-friendly, with results visible within just 10 minutes, a significant advantage in critical times. The kit includes a cassette, buffer, and package insert stored in a single compact pack. Each pack contains 20 tests, making it an economical choice for both small and large scale applications. The tests are easy to conduct using either nasal or nasopharyngeal swabs, offering versatility and convenience. Our device is CE-certified, signifying its compliance with health, safety, and environmental protection standards for products sold within the European Economic Area. This certification is a testament to QL Biotech’s commitment to delivering reliable and safe medical devices. The SARS-COV-2/Influenza A+B Antigen Combo Rapid Test Device is designed for storage in conditions ranging from 2 to 30℃, ensuring its durability. With a shelf life of up to 2 years, it proves to be not only a high-quality but also a long-lasting solution.



In using this device, please note that the same test procedure applies as with the SARS-COV-2 Antigen Rapid Test Device (Swab). Results should strictly be read within 10 minutes, and any interpretation after 20 minutes is deemed invalid. In conclusion, the SARS-COV-2/Influenza A+B Antigen Combo Rapid Test Device by QL Biotech is a reliable solution for the Detection of Canine C Reactive Protein. Its speed, accuracy, and convenience ensure that it is an ideal choice for every medical professional.